Jose Luis Pelaez Inc/DigitalVision via Getty Images Miplyffa (arimoclomol), the first ever medication specifically approved for Niemann-Pick disease type C, is now available from Zevra Therapeutics ( NASDAQ: ZVRA ). The drug is approved for use in combination with Johnson & Johnson's ( JNJ ) Zavesca (miglustat) for the treatment of patients.
Back to Health Page
